The Lung Cancer Genomic Testing Market is gaining traction as cancer care becomes increasingly dependent on molecular information. The expansion of targeted therapies, rising investment in biomarker research, and demand for individualized treatment are encouraging hospitals and laboratories to expand genomic testing capabilities. Increasing awareness of precision medicine is further supporting adoption.

A major trend is the movement toward comprehensive genomic profiling. NGS platforms can examine multiple genes and biomarkers in a single workflow, potentially reducing the need for repeated individual tests. PCR remains widely used for focused molecular analysis, while newer approaches are helping laboratories improve sensitivity, efficiency, and the breadth of genomic information available to clinicians.

Sample collection is another area of innovation. Traditional tissue biopsies remain important, but liquid biopsy using blood samples is attracting interest because it can provide a less invasive source of tumor-related genetic information. Testing of tissue, blood, urine, and pleural fluid allows laboratories to select approaches based on sample availability and clinical needs.

The market has strong opportunities across North America, Europe, and Asia-Pacific. North America benefits from advanced healthcare infrastructure and substantial research and development activity, while Asia-Pacific is supported by expanding healthcare facilities, rising investment, and growing awareness of molecular diagnostics. The increasing use of biomarker testing and companion diagnostics is also creating opportunities for laboratories and technology providers.

In the coming years, AI and advanced data analytics are expected to become more closely integrated with genomic testing. Automated interpretation, cloud-based analysis, and digital reporting can help manage complex datasets and support faster clinical workflows. Together with liquid biopsy and increasingly comprehensive sequencing, these innovations could strengthen the contribution of genomic testing to personalized lung cancer care.